Savara Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Savara kazanç ve gelirinin sırasıyla yıllık 54.2% ve 65.8% oranında artması tahmin edilirken, EPS'nin yıllık 54.5% oranında büyümesi bekleniyor.

Anahtar bilgiler

54.2%

Kazanç büyüme oranı

54.5%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.0%
Gelir büyüme oranı	65.8%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	06 Nov 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Savara's rare lung disorder drug gets promising innovative medicine status in UK

Aug 26

Savara GAAP EPS of -$0.06 in-line

Aug 11

Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?

Jan 24

Is Savara (NASDAQ:SVRA) A Risky Investment?

Jul 05

Savara: They Failed Once, But They Are Trying Again

Jun 07

The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares

Mar 17

Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares

Feb 26

Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex

Nov 24

Savara EPS misses by $0.01

Nov 05

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGS:SVRA - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	56	-32	-82	N/A	5
12/31/2025	2	-86	-86	N/A	7
12/31/2024	N/A	-85	-79	N/A	7
6/30/2024	N/A	-75	-72	-72	N/A
3/31/2024	N/A	-64	-60	-60	N/A
12/31/2023	N/A	-55	-51	-51	N/A
9/30/2023	N/A	-49	-44	-44	N/A
6/30/2023	N/A	-43	-39	-39	N/A
3/31/2023	N/A	-40	-38	-38	N/A
12/31/2022	N/A	-38	-35	-35	N/A
9/30/2022	N/A	-39	-35	-35	N/A
6/30/2022	N/A	-39	-36	-36	N/A
3/31/2022	N/A	-41	-39	-39	N/A
12/31/2021	N/A	-43	-40	-40	N/A
9/30/2021	0	-45	-43	-43	N/A
6/30/2021	0	-46	-41	-41	N/A
3/31/2021	0	-44	-36	-36	N/A
12/31/2020	0	-50	-43	-40	N/A
9/30/2020	0	-68	-41	-37	N/A
6/30/2020	N/A	-69	-45	-42	N/A
3/31/2020	N/A	-81	-51	-47	N/A
12/31/2019	N/A	-78	-45	-45	N/A
9/30/2019	N/A	-57	-46	-46	N/A
6/30/2019	N/A	-57	-43	-43	N/A
3/31/2019	N/A	-47	-41	-40	N/A
12/31/2018	N/A	-62	-39	-39	N/A
9/30/2018	N/A	-58	-39	-38	N/A
6/30/2018	N/A	-52	-38	-38	N/A
3/31/2018	N/A	-53	N/A	-35	N/A
12/31/2017	N/A	-31	N/A	-28	N/A
9/30/2017	0	-28	N/A	-21	N/A
6/30/2017	0	-25	N/A	-16	N/A
3/31/2017	0	-14	N/A	-9	N/A
12/31/2016	0	-11	N/A	-8	N/A
12/31/2015	0	-9	N/A	-5	N/A
12/31/2014	2	-6	N/A	-4	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: SVRA önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 2.6% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: SVRA önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: SVRA önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: SVRA şirketinin gelirinin (yıllık 65.8% ) US pazarından (yıllık 8.9% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: SVRA şirketinin gelirinin (yıllık 65.8% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: SVRA 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Savara Gelecekteki Büyüme

Future kriter kontrolleri 5/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target increased by 19% to US$10.71

No longer forecast to breakeven

Forecast to breakeven in 2026

No longer forecast to breakeven

Price target increased by 7.3% to US$5.50

Price target increased by 7.5% to US$5.38

Recent updates

Savara Appoints Braden Parker as Chief Commercial Officer

Savara: Trial Successful, But I'm Only Half Convinced

Price target increased by 19% to US$10.71

Savara: Today's Data 'Win' Rouses Market All Too Briefly

Savara Inc. Announces Positive Results from the Pivotal, Phase 3 IMPALA-2 clinical trial

Savara: The Binary Bet On Phase 3 Data

Savara Inc. has filed a Follow-on Equity Offering in the amount of $100 million.

Savara Inc., Annual General Meeting, Jun 06, 2024

Dr. Ricky Sun Notifies the Board of Directors of Savara Inc. of His Intention Not to Stand for Reelection

Savara to Present New Data on Autoimmune Pulmonary Alveolar Proteinosis at the American Thoracic Society International Conference 2024

No longer forecast to breakeven

New minor risk - Profitability

Chairman & CEO recently sold US$396k worth of stock

Forecast to breakeven in 2026

Savara Inc. Introduces Apap Clearpath, A Gm-Csf Autoantibody Blood Test to Detect Autoimmune Pulmonary Alveolar Proteinosis

Health Check: How Prudently Does Savara (NASDAQ:SVRA) Use Debt?

New minor risk - Profitability

No longer forecast to breakeven

Price target increased by 7.3% to US$5.50

Price target increased by 7.5% to US$5.38

New minor risk - Shareholder dilution

New minor risk - Share price stability

Savara Inc. has completed a Follow-on Equity Offering in the amount of $79.994334 million.

Savara Inc. Completes Enrollment of Pivotal Phase 3 Impala-2 Trial of Molgramostim Nebulizer Solution (Molgramostim) in Autoimmune Pulmonary Alveolar Proteinosis

Independent Director recently bought US$259k worth of stock

No longer forecast to breakeven

Price target increased by 21% to US$4.60

Savara Inc. Announces New Leadership Appointments

Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Savara Inc. Announces New Leadership Appointments

Independent Director recently bought US$56k worth of stock

Forecast to breakeven in 2025

Independent Director recently bought US$82k worth of stock

Independent Director recently bought US$68k worth of stock

Is Savara (NASDAQ:SVRA) Using Too Much Debt?

Independent Director recently bought US$187k worth of stock

Independent Director recently bought US$142k worth of stock

Savara Announces Resignation of Badrul Chowdhury as Chief Medical Officer, Effective on September 9, 2022

Savara's rare lung disorder drug gets promising innovative medicine status in UK

Savara GAAP EPS of -$0.06 in-line

Independent Director recently bought US$138k worth of stock

Savara Inc. has completed a Follow-on Equity Offering in the amount of $60 million.

Savara Inc., Annual General Meeting, Jun 02, 2022

Price target increased to US$4.50

Does Savara (NASDAQ:SVRA) Have A Healthy Balance Sheet?

Independent Director recently bought US$64k worth of stock

Independent Director recently bought US$215k worth of stock

Independent Director recently bought US$176k worth of stock

Independent Director recently bought US$115k worth of stock

Is Savara (NASDAQ:SVRA) A Risky Investment?

Savara Inc. Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Trial

Savara Inc.(NasdaqGS:SVRA) dropped from Russell 3000E Value Index

Savara: They Failed Once, But They Are Trying Again

Independent Director recently bought US$81k worth of stock

The Independent Director of Savara Inc. (NASDAQ:SVRA), David Ramsay, Just Bought 565% More Shares

Savara Inc. has completed a Follow-on Equity Offering in the amount of $113.011275 million.

Revenue and earnings beat expectations

Trade Alert: The Chairman & CEO Of Savara Inc. (NASDAQ:SVRA), Matthew Pauls, Has Just Spent US$50k Buying 4,415% More Shares

Chairman & CEO recently bought US$50k worth of stock

New 90-day high: US$2.06

New 90-day high: US$1.97

New 90-day high: US$1.57

Price target lowered to US$2.67

Savara Inc. Provides Update on Molgradex in aPAP and the Phase 3 IMPALA 2 Trial

Savara Inc. Announces CEO Change

New 90-day high: US$1.44

Price target lowered to US$3.83

Savara's IMPALA 2 Trial Seems Well-Tailored To Get Positive Phase 3 Data For Molgradex

New 90-day low: US$1.00